In 2025, Hansoh Pharmaceutical Group completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Hansoh Pharmaceutical Group has also provided a category-level breakdown for 4 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 11,833.89a | 13,163.25a | 10,546.85a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 97,828.71a | 88,227.05a | 81,565.21a | |
Total Scope 3 | 93,115.14a | 55,724.79b | 13,966.68b | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 5.5127a | 7.8353a | 7.4186a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Hansoh Pharmaceutical Group amounted to 109,662.6 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Hansoh Pharmaceutical Group increased by 8.16%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Hansoh Pharmaceutical Group were 11,833.89 metric tons of CO₂ equivalent (tCO₂e).a
Since 2021, Hansoh Pharmaceutical Group's Scope 1 emissions have increased by 89.16%, reflecting a rising long-term trend in Scope 1 emissions over time.ac
Compared to the previous year (2024), Hansoh Pharmaceutical Group's Scope 1 emissions decreased by 10.1%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2025, Hansoh Pharmaceutical Group reported Scope 2 greenhouse gas (GHG) emissions of 97,828.71 tCO₂e without specifying the calculation method.a
Since 2021, Hansoh Pharmaceutical Group's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have decreased by 15.72%, reflecting a declining long-term trend in Scope 2 emissions over time.ac
Compared to the previous year (2024), Hansoh Pharmaceutical Group's Scope 2 emissions (Unspecified Calculation Method) rose by 10.88% in 2025, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2025, Hansoh Pharmaceutical Group reported its Scope 2 emissions using an unspecified methodology.a
In 2025, Hansoh Pharmaceutical Group reported 93,115.14 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Hansoh Pharmaceutical Group includes a breakdown across 4 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, Hansoh Pharmaceutical Group reported total Scope 3 emissions of 93,115.14 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2024), Hansoh Pharmaceutical Group's Scope 3 emissions increased by 67.1%, suggesting that the company faced challenges in reducing emissions across its value chain.ab
In 2025, Hansoh Pharmaceutical Group reported emissions for 4 out of the 15 Scope 3 categories defined by the GHG Protocol.a
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
In 2025, the largest contributors to Hansoh Pharmaceutical Group's Scope 3 emissions were:a
In 2025, Hansoh Pharmaceutical Group reported Scope 1 greenhouse gas (GHG) emissions of 11,833.89 tCO₂e and total revenues of USD 2,147 millions. This translates into an emissions intensity of 5.51 tCO₂e per millions USD.a
In 2025, Hansoh Pharmaceutical Group reported a Scope 1 emissions intensity of 5.51 tCO₂e per millions USD. Compared to the peer group median of 25.37, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, Hansoh Pharmaceutical Group ranked 5 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Hansoh Pharmaceutical Group among the top performers, with one of the lowest emissions intensities relative to peers.a
In 2025, Hansoh Pharmaceutical Group reported a total carbon footprint of 202,777.74 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 29.06% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.ab
The largest contributor to Hansoh Pharmaceutical Group's total carbon footprint was Scope 2 emissions, accounting for 48.24% of the company's total carbon footprint, followed by Scope 3 emissions at 45.92%.a